Famotidine in Schizophrenia

NCT01946295 ↗

Phase 2/3 Unknown 140 enrolled Jesper Ekelund Ahokas foundation, Finland · collab City of Helsinki · collab Karolinska Institutet · collab Region Stockholm · collab Stanley Medical Research Institute · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Objective of the trial is to study if famotidine add-on treatment is more effective than placebo add-on in reducing symptoms of schizophrenia among patients receiving insufficient response to ongoing antipsychotic treatment.

Timeline

Start: 2014-03
Primary completion: 2016-08
Completion: 2016-08

Publications

Background Meskanen K, Ekelund H, Laitinen J, Neuvonen PJ, Haukka J, Panula P, Ekelund J. A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clin Psychopharmacol. 2013 Aug;33(4):472-8. doi: 10.1097/JCP.0b013e3182970490.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Famotidine	Other / unclassified	100 mg	Oral

Famotidine in Schizophrenia

Summary

Timeline

Publications

Drugs

Indications